La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Revvity Croissance future

Future contrôle des critères 3/6

Revvity devrait augmenter ses bénéfices et son chiffre d'affaires de 25.8% et de 6.2% par an respectivement. Le BPA devrait croître de de 26.4% par an. Le rendement des capitaux propres devrait être 8.1% dans 3 ans.

Informations clés

25.8%

Taux de croissance des bénéfices

26.4%

Taux de croissance du BPA

Life Sciences croissance des bénéfices	18.1%
Taux de croissance des recettes	6.2%
Rendement futur des capitaux propres	8.1%
Couverture par les analystes	Good
Dernière mise à jour	27 Aug 2024

Mises à jour récentes de la croissance future

Recent updates

An Intrinsic Calculation For Revvity, Inc. (NYSE:RVTY) Suggests It's 49% Undervalued

Jan 04

Revvity: More Than A Name Change Is Needed For PerkinElmer

Dec 29

Why We're Not Concerned About Revvity, Inc.'s (NYSE:RVTY) Share Price

Dec 20

Is Revvity (NYSE:RVTY) Using Too Much Debt?

Oct 07

Revvity: Recent Investments, Acquisitions, Not Pulling Economic Weight (Rating Downgrade)

Oct 04

At US$108, Is Revvity, Inc. (NYSE:RVTY) Worth Looking At Closely?

Sep 22

An Intrinsic Calculation For Revvity, Inc. (NYSE:RVTY) Suggests It's 40% Undervalued

Aug 17

Revvity: New Name - But New Investment Outlook? Reiterate Buy

Jul 18

Revvity (NYSE:RVTY) Seems To Use Debt Quite Sensibly

Jul 03

What Does Revvity, Inc.'s (NYSE:RVTY) Share Price Indicate?

Jun 17

Calculating The Fair Value Of Revvity, Inc. (NYSE:PKI)

May 16

We Think PerkinElmer (NYSE:PKI) Can Stay On Top Of Its Debt

Mar 28

When Should You Buy PerkinElmer, Inc. (NYSE:PKI)?

Mar 13

PerkinElmer Q4 2022 Earnings Preview

Feb 13

A Look At The Intrinsic Value Of PerkinElmer, Inc. (NYSE:PKI)

Feb 10

PerkinElmer: Capital Budgeting A Key Factor To The Investment Debate

Jan 31

Danaher earnings weigh on other life sciences tools, services companies

Jan 24

PerkinElmer says Q4 results will meet or exceed prior guidance

Jan 09

PerkinElmer (NYSE:PKI) Has A Pretty Healthy Balance Sheet

Dec 27

Prévisions de croissance des bénéfices et des revenus

NYSE:RVTY - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	3,173	402	914	810	11
12/31/2025	2,961	334	793	743	15
12/31/2024	2,776	246	549	630	14
6/30/2024	2,708	197	383	469	N/A
3/31/2024	2,726	183	97	175	N/A
12/31/2023	2,751	180	10	91	N/A
10/1/2023	2,796	213	-50	34	N/A
7/2/2023	2,837	250	153	227	N/A
4/2/2023	3,024	353	380	460	N/A
1/1/2023	3,312	513	594	680	N/A
10/2/2022	3,599	599	790	876	N/A
7/3/2022	3,748	637	932	1,030	N/A
4/3/2022	3,483	694	1,122	1,220	N/A
1/2/2022	3,828	889	1,325	1,411	N/A
10/3/2021	4,155	1,086	1,478	1,557	N/A
7/4/2021	4,257	1,155	1,380	1,455	N/A
4/4/2021	4,438	1,074	1,234	1,306	N/A
1/3/2021	2,663	631	829	892	N/A
10/4/2020	3,234	412	545	625	N/A
7/5/2020	2,977	294	444	521	N/A
4/5/2020	2,887	226	352	429	N/A
12/29/2019	2,884	228	282	363	N/A
9/29/2019	2,835	235	217	308	N/A
6/30/2019	2,802	251	199	294	N/A
3/31/2019	2,783	247	225	320	N/A
12/30/2018	2,778	237	218	311	N/A
9/30/2018	2,663	128	203	280	N/A
7/1/2018	2,543	149	178	245	N/A
4/1/2018	2,387	147	N/A	220	N/A
12/31/2017	2,257	157	N/A	288	N/A
10/1/2017	2,182	258	N/A	309	N/A
7/2/2017	2,142	215	N/A	324	N/A
4/2/2017	2,132	210	N/A	372	N/A
1/1/2017	2,116	216	N/A	351	N/A
10/2/2016	1,999	198	N/A	327	N/A
7/3/2016	2,048	199	N/A	314	N/A
4/3/2016	2,076	190	N/A	281	N/A
1/3/2016	2,105	189	N/A	287	N/A
10/4/2015	2,263	176	N/A	258	N/A
6/28/2015	2,241	164	N/A	261	N/A
3/29/2015	2,234	167	N/A	252	N/A
12/28/2014	2,070	130	N/A	282	N/A
9/28/2014	2,221	203	N/A	257	N/A
6/29/2014	2,201	201	N/A	242	N/A
3/30/2014	2,185	176	N/A	215	N/A
12/29/2013	2,158	174	N/A	159	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de RVTY ( 25.8% par an) est supérieure au taux d'épargne ( 2.5% ).

Bénéfices vs marché: Les bénéfices de RVTY ( 25.8% par an) devraient croître plus rapidement que le marché US ( 15.2% par an).

Croissance élevée des bénéfices: Les bénéfices de RVTY devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de RVTY ( 6.2% par an) devrait croître plus lentement que le marché de US ( 8.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de RVTY ( 6.2% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de RVTY devrait être faible dans 3 ans ( 8.1 %).

Revvity Croissance future

Future contrôle des critères 3/6

Informations clés

Mises à jour récentes de la croissance future

Price target increased by 8.2% to US$134

Revvity, Inc. Updates Earnings Guidance for the Full Year 2024

Revvity, Inc. Updates Earnings Guidance for the Full Year 2024

Revvity, Inc. Re-Affirms Earnings Guidance for the Full Year 2024

Price target increased by 8.9% to US$122

Revvity, Inc. Provides Revenue Guidance for the Full Year of 2024

Recent updates

Getting In Cheap On Revvity, Inc. (NYSE:RVTY) Might Be Difficult

Second quarter 2024 earnings: EPS misses analyst expectations

Price target increased by 8.2% to US$134

Revvity, Inc. Updates Earnings Guidance for the Full Year 2024

Dividend of US$0.07 announced

Revvity Board Declares Quarterly Dividend, Payable on November 8, 2024

When Should You Buy Revvity, Inc. (NYSE:RVTY)?

Upcoming dividend of US$0.07 per share

Revvity, Inc. to Report Q2, 2024 Results on Jul 29, 2024

Revvity: Continued Struggles, 2024 Becoming A Lost Year

Is Revvity (NYSE:RVTY) Using Too Much Debt?

First quarter 2024 earnings: EPS misses analyst expectations

Revvity, Inc. Updates Earnings Guidance for the Full Year 2024

Dividend of US$0.07 announced

Revvity, Inc. Declares Quarterly Dividend, Payable on August 9, 2024

Revvity Unveils A New Era of Automated Tuberculosis Testing

Upcoming dividend of US$0.07 per share

Revvity, Inc. to Report Q1, 2024 Results on Apr 29, 2024

Why We're Not Concerned About Revvity, Inc.'s (NYSE:RVTY) Share Price

Revvity: Enter Now As Reorganization Takes Shape

Revvity, Inc. Re-Affirms Earnings Guidance for the Full Year 2024

Revvity Signals Software Introduces Signals ChemDraw Offering to Set New Standard for Cloud-Native Chemistry Communication

Revvity, Inc. Introduces New Workflow to Accelerate Newborn Sequencing Research

We Think Revvity (NYSE:RVTY) Can Stay On Top Of Its Debt

Investors Can Find Comfort In Revvity's (NYSE:RVTY) Earnings Quality

Revvity Signals Software Unveils Signals Clinical Solution to Accelerate Critical Clinical Trial Insights and Data-Driven Decisions

CEO, President & Director notifies of intention to sell stock

New minor risk - Earnings quality

Price target increased by 8.9% to US$122

Revvity Showcases Cutting-Edge Solutions at SLAS2024

Full year 2023 earnings: EPS exceeds analyst expectations

Revvity, Inc. Provides Revenue Guidance for the Full Year of 2024

Dividend of US$0.07 announced

Revvity, Inc., Annual General Meeting, Apr 23, 2024

Revvity, Inc. Announces Board Elections, Effective February 1, 2024

Should You Think About Buying Revvity, Inc. (NYSE:RVTY) Now?

Upcoming dividend of US$0.07 per share at 0.3% yield

Revvity, Inc. to Report Q4, 2023 Results on Feb 01, 2024

Revvity, Inc. Provides Revenue Guidance for the Fourth Quarter 2023

An Intrinsic Calculation For Revvity, Inc. (NYSE:RVTY) Suggests It's 49% Undervalued

Revvity: More Than A Name Change Is Needed For PerkinElmer

Why We're Not Concerned About Revvity, Inc.'s (NYSE:RVTY) Share Price

Revvity, Inc. Launches EONIS Q System, Enabling Faster, Simplified Newborn Screening for SMA and SCID

Revvity, Inc. Launches EONIS Q System, Enabling Faster, Simplified Newborn Screening for SMA and SCID

Consensus EPS estimates fall by 15%

Price target decreased by 22% to US$107

Revvity, Inc. Provides Earnings Guidance for the Full Year 2023

New minor risk - Earnings quality

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Revvity Board Declares Quarterly Dividend, Payable on February 9, 2024

Upcoming dividend of US$0.07 per share at 0.3% yield

Revvity, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Is Revvity (NYSE:RVTY) Using Too Much Debt?

Revvity: Recent Investments, Acquisitions, Not Pulling Economic Weight (Rating Downgrade)

Revvity Expands Access to Base Editing Technology with Aim to Accelerate Discovery to Cure

At US$108, Is Revvity, Inc. (NYSE:RVTY) Worth Looking At Closely?

Revvity, Inc. Unveils Several Next-Generation Preclinical Imaging Technologies to Help Scientists Drive Breakthrough Discoveries

An Intrinsic Calculation For Revvity, Inc. (NYSE:RVTY) Suggests It's 40% Undervalued

Revvity, Inc. Provides Earnings Guidance for the Full Year 2023

New minor risk - Earnings quality

Second quarter 2023 earnings: EPS misses analyst expectations

Now 21% undervalued after recent price drop

Revvity Declares Quarterly Dividend, Payable on November 10, 2023

Revvity: New Name - But New Investment Outlook? Reiterate Buy

Revvity, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Upcoming dividend of US$0.07 per share at 0.2% yield

Revvity (NYSE:RVTY) Seems To Use Debt Quite Sensibly

Honeycomb Biotechnologies and Revvity Launch New Solutions to Expand the Frontiers of Single Cell Research

Now 22% undervalued after recent price drop